

QIBA Process Committee Meeting
Tuesday, March 15, 2022, at 2 pm (CT)
Meeting Summary

Attendees:

Kevin O'Donnell, MASC (Chair)
Michael Boss, PhD (Vice Chair)

Nancy Obuchowski, PhD
Nicholas Petrick, PhD

David Soltysik, PhD
Daniel Sullivan, MD

RSNA Staff:

Susan Stanfa

Topics Discussed:

- Review of [Estimates of Precision Guidance Text](#) drafted by Dr. Obuchowski
 - Since Claim in Profile stages 1 – 3 is a hypothesis, it should not be cited
 - Test-retest, bias, or linearity requirements for performance not recommended except for those expected be part of site conformance when the Stage 4 Profile is published. Those need to be present in Stages 1-3 so people can comment on and/or test their practicality.
 - In Profile stage 4, The assumptions underlying the Claim have been verified in a multi-site trial
 - To conform to stage 4 and utilize the Claim, sites use data from the trial to show *non-inferiority* with claimed precision and bias (showing linearity would be a BC role, not a site role)
 - Definition of non-inferiority needed, e.g., wCV not more than 1%, 2%, 3% greater than Claim
 - In a Claim-Confirmed (stage 4) study, the Claim has been verified in a multi-site, multi-vendor study and the results are expected to be generalizable in similar settings
 - Exact number of sites and vendors to be defined
 - Test of null hypothesis that $wCV > \text{Claim}$ vs. alternative that $wCV \leq \text{Claim}$
 - This stage should include a refinement of the Claim
- [Streamlined Profile Template](#) – Drs. Boss and Soltysik
 - Use of this template has encouraged the fMRI BC to limit checklists to only items required to achieve Claim
 - Extraneous details moved to Appendix A, which was renamed to avoid confusion with checklist specifications

Next Steps / Action Items:

- Dr. Obuchowski to finish guidance text for PC review/wiki posting by the end of March re: [estimates of precision](#) required when Profiles advance through stages vs. when imaging sites attempt Profile conformance
 - CT Volumetry Profile ballot to be distributed to BC voters and [Estimates of Precision Guidance Text](#) to be posted on QIBA Wiki
- Naming convention to distinguish between same-stage Profile versions and facilitate referencing / citation
 - Year edition was suggested, though a contingency plan regarding multiple Profile updates within the same year would be needed
 - Suggestion that minor changes be indicated with .1, .2, .3, etc.
 - Profile Editors to be contacted with explanation of intentions for meetings and suggestions for topics/issues/questions and logistics/timing to be requested
 - Process Cmte leaders to reach out to CC Co-chairs for feedback on Profile versioning
 - Profile nickname vs. formal name; how titles look and sound to reference
- [Agenda items for April 5 Process Committee Meeting](#) include:
 - [Streamlined Profile Template](#) – fMRI BC progress toward public comment (stage 1) and barriers (Drs. Boss, Elsinger and Soltysik)
 - [Profile Maintenance/Versioning/Naming](#) (Drs. Boss, Pepin, and Yap)

- [Process Committee Profile Selection Process](#)
 - Number of tasks vs. bandwidth
 - How to identify when a proposal is a practical use of time and would characterize a successful Profile
- [Estimates of Precision Guidance Text](#) – Dr. Obuchowski plans for wrapping up

Next Process Committee Meeting: Tuesday, April 5, 2022, at 2 p.m. (CT) **[1st & 3rd Tuesdays of each month]**